| Assay ID | Title | Year | Journal | Article |
|---|
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
| Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347172 | Secondary qRT-PCR qHTS assay for selected Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347158 | ZIKV-mCherry secondary qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347152 | Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347168 | HepG2 cells viability qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347167 | Vero cells viability qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347156 | DAPI mCherry counterscreen qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347170 | Vero cells viability counterscreen for qRT-PCR qHTS assay of selected Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347163 | 384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347424 | RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
| Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347171 | Orthogonal mCherry assay for qRT-PCR qHTS of selected Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347164 | 384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347153 | Confirmatory screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347161 | Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347425 | Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
| Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347149 | Furin counterscreen qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347169 | Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1347407 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1149697 | Antimicrobial activity against Salmonella typhi assessed as growth inhibition after 24 hrs by two-fold serial dilution technique | 1977 | Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
| Synthesis of 5-chloro-3'-nitro-4'-substituted salicylanilides, a new series of anthelmintic and antimicrobial agents. |
| AID1149692 | Antimicrobial activity against Microsporum canis assessed as growth inhibition after 24 hrs by two-fold serial dilution technique | 1977 | Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
| Synthesis of 5-chloro-3'-nitro-4'-substituted salicylanilides, a new series of anthelmintic and antimicrobial agents. |
| AID25563 | Dissociation constant is the negative logarithm of the equilibrium coefficient of the neutral and charged forms of the compound | 1981 | Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
| Potential salicylamide antiplaque agents: in vitro antibacterial activity against Actinomyces viscosus. |
| AID407847 | Inhibition of HCV 1b NS5B polymerase | 2008 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11
| Identification of halosalicylamide derivatives as a novel class of allosteric inhibitors of HCV NS5B polymerase. |
| AID741324 | Induction of internalization of Frizzled1-GFP (unknown origin) expressed in human U2OS cells at 12.5 uM after 6 hrs by confocal microscopy | 2013 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
| Small molecule modulators of Wnt/β-catenin signaling. |
| AID30703 | In vitro antibacterial activity against Actinomycetes naeslundii 12104 | 1981 | Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
| Potential salicylamide antiplaque agents: in vitro antibacterial activity against Actinomyces viscosus. |
| AID30576 | In vitro antibacterial activity against Actinomyces viscosus M-100-2000 | 1981 | Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
| Potential salicylamide antiplaque agents: in vitro antibacterial activity against Actinomyces viscosus. |
| AID30577 | Minimum inhibitory concentration against Actinomyces viscosus | 1986 | Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
| 5-(Alkylsulfonyl)salicylanilides as potential dental antiplaque agents. |
| AID30711 | Evaluated for the in vitro minimum bactericidal concentration (MBC) against periopathogenic Actinomycetes viscosus bacteria | 1987 | Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
| Substituted 2-(2-hydroxyphenyl)benzimidazoles as potential agents for the control of periodontal diseases. |
| AID30552 | Evaluated for the in vitro minimum bactericidal concentration (MBC) against periopathogenic Actinobacillus actinomycetemcommitans bacteria | 1987 | Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
| Substituted 2-(2-hydroxyphenyl)benzimidazoles as potential agents for the control of periodontal diseases. |
| AID18966 | Distribution coefficient between octanol and aqueous phase at pH7.2 | 1981 | Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
| Potential salicylamide antiplaque agents: in vitro antibacterial activity against Actinomyces viscosus. |
| AID18964 | Observed inhibitory activity against various Actinomycetes strains | 1981 | Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
| Potential salicylamide antiplaque agents: in vitro antibacterial activity against Actinomyces viscosus. |
| AID1149699 | Antimicrobial activity against Bacillus subtilis assessed as growth inhibition after 24 hrs by two-fold serial dilution technique | 1977 | Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
| Synthesis of 5-chloro-3'-nitro-4'-substituted salicylanilides, a new series of anthelmintic and antimicrobial agents. |
| AID1149698 | Antimicrobial activity against Escherichia coli assessed as growth inhibition after 24 hrs by two-fold serial dilution technique | 1977 | Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
| Synthesis of 5-chloro-3'-nitro-4'-substituted salicylanilides, a new series of anthelmintic and antimicrobial agents. |
| AID30700 | In vitro antibacterial activity against Actinomycetes israelii 12836 | 1981 | Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
| Potential salicylamide antiplaque agents: in vitro antibacterial activity against Actinomyces viscosus. |
| AID30705 | In vitro antibacterial activity against Actinomycetes naeslundii 8115 | 1981 | Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
| Potential salicylamide antiplaque agents: in vitro antibacterial activity against Actinomyces viscosus. |
| AID30714 | In vitro antibacterial activity against Actinomycetes viscosus T14V | 1981 | Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
| Potential salicylamide antiplaque agents: in vitro antibacterial activity against Actinomyces viscosus. |
| AID209598 | Maximum percentage inhibition against Streptococcus mutans at a concentration of 0.2% w/v | 1986 | Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
| 5-(Alkylsulfonyl)salicylanilides as potential dental antiplaque agents. |
| AID19264 | Partition coefficient is determined in octanol/buffer solution | 1981 | Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
| Potential salicylamide antiplaque agents: in vitro antibacterial activity against Actinomyces viscosus. |
| AID1149690 | Antimicrobial activity against Cryptococcus neoformans assessed as growth inhibition after 24 hrs by two-fold serial dilution technique | 1977 | Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
| Synthesis of 5-chloro-3'-nitro-4'-substituted salicylanilides, a new series of anthelmintic and antimicrobial agents. |
| AID30701 | In vitro antibacterial activity against Actinomycetes israelii 28360 | 1981 | Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
| Potential salicylamide antiplaque agents: in vitro antibacterial activity against Actinomyces viscosus. |
| AID41088 | Evaluated for the in vitro minimum bactericidal concentration (MBC) against periopathogenic Bacteroides gingivalis bacteria | 1987 | Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
| Substituted 2-(2-hydroxyphenyl)benzimidazoles as potential agents for the control of periodontal diseases. |
| AID1149688 | Antimicrobial activity against penicillin-resistant Staphylococcus aureus assessed as growth inhibition after 24 hrs by two-fold serial dilution technique | 1977 | Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
| Synthesis of 5-chloro-3'-nitro-4'-substituted salicylanilides, a new series of anthelmintic and antimicrobial agents. |
| AID1149691 | Antimicrobial activity against Trichophyton mentagrophytes assessed as growth inhibition after 24 hrs by two-fold serial dilution technique | 1977 | Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
| Synthesis of 5-chloro-3'-nitro-4'-substituted salicylanilides, a new series of anthelmintic and antimicrobial agents. |
| AID1149689 | Antimicrobial activity against Agrobacterium tumefaciens assessed as growth inhibition after 24 hrs by two-fold serial dilution technique | 1977 | Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
| Synthesis of 5-chloro-3'-nitro-4'-substituted salicylanilides, a new series of anthelmintic and antimicrobial agents. |
| AID209596 | The compound was tested for it's inhibitory activity against Streptococcus mutans | 1986 | Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
| 5-(Alkylsulfonyl)salicylanilides as potential dental antiplaque agents. |
| AID30574 | Maximum percentage inhibition against Actinomyces viscosus 6715-13WT at a concentration of 0.2% w/v | 1986 | Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
| 5-(Alkylsulfonyl)salicylanilides as potential dental antiplaque agents. |
| AID30582 | In vitro antibacterial activity against Actinomycetes israelii 10048 | 1981 | Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
| Potential salicylamide antiplaque agents: in vitro antibacterial activity against Actinomyces viscosus. |
| AID30572 | Compound was tested for it's inhibitory activity against Actinomyces viscosus M100-2000 | 1986 | Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
| 5-(Alkylsulfonyl)salicylanilides as potential dental antiplaque agents. |
| AID1149693 | Antimicrobial activity against Aspergillus niger assessed as growth inhibition after 24 hrs by two-fold serial dilution technique | 1977 | Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
| Synthesis of 5-chloro-3'-nitro-4'-substituted salicylanilides, a new series of anthelmintic and antimicrobial agents. |
| AID1802974 | EGFR Inhibition Assay from Article 10.3109/14756361003671060: \\Synthesis and antiproliferative activities against Hep-G2 of salicylanide derivatives: potent inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase.\\ | 2011 | Journal of enzyme inhibition and medicinal chemistry, Feb, Volume: 26, Issue:1
| Synthesis and antiproliferative activities against Hep-G2 of salicylanide derivatives: potent inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |